These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 29428228)

  • 21. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition.
    Harvey M; Prosser LA; Rose AM; Ortega-Sanchez IR; Harpaz R
    Pain; 2020 Feb; 161(2):361-368. PubMed ID: 31599852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study.
    Díez-Domingo J; Curran D; Cambronero MDR; Garcia-Martinez JA; Matthews S
    Adv Ther; 2021 Jun; 38(6):3325-3341. PubMed ID: 34013498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
    Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
    Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
    Johnson RW
    Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Herpes zoster and postherpetic neuralgia.
    Johnson RW
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):21-6. PubMed ID: 20192714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of herpes zoster vaccine in Canada.
    Najafzadeh M; Marra CA; Galanis E; Patrick DM
    Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Burden of herpes zoster and postherpetic neuralgia: Incidence, proportion, and associated costs in the French population aged 50 or over].
    Mick G; Gallais JL; Simon F; Pinchinat S; Bloch K; Beillat M; Serradell L; Derrough T
    Rev Epidemiol Sante Publique; 2010 Dec; 58(6):393-401. PubMed ID: 21094001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination against Herpes Zoster and Postherpetic Neuralgia.
    Oxman MN; Levin MJ;
    J Infect Dis; 2008 Mar; 197 Suppl 2(Suppl 2):S228-36. PubMed ID: 18419402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
    Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H
    Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing incidence associated with herpes zoster infection in British Columbia, Canada.
    Marra F; Chong M; Najafzadeh M
    BMC Infect Dis; 2016 Oct; 16(1):589. PubMed ID: 27765026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study.
    Alicino C; Trucchi C; Paganino C; Barberis I; Boccalini S; Martinelli D; Pellizzari B; Bechini A; Orsi A; Bonanni P; Prato R; Iannazzo S; Icardi G
    Hum Vaccin Immunother; 2017 Feb; 13(2):399-404. PubMed ID: 27925843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Herpes zoster incidence in Germany - an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort.
    Caputo M; Horn J; Karch A; Akmatov MK; Becher H; Braun B; Brenner H; Castell S; Fischer B; Giani G; Günther K; Hoffmann B; Jöckel KH; Keil T; Klüppelholz B; Krist L; Leitzmann MF; Lieb W; Linseisen J; Meisinger C; Moebus S; Obi N; Pischon T; Schipf S; Schmidt B; Sievers C; Steinbrecher A; Völzke H; Mikolajczyk R
    BMC Infect Dis; 2019 Jan; 19(1):99. PubMed ID: 30700258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination: a new option to reduce the burden of herpes zoster.
    Mick G
    Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV
    Eriksson J; Hunger M; Bourhis F; Thorén R; Popmihajlov Z; Finelli L; Jiang Y
    Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):613-621. PubMed ID: 31721601
    [No Abstract]   [Full Text] [Related]  

  • 35. Herpes zoster and postherpetic neuralgia in older adults.
    Schmader K
    Clin Geriatr Med; 2007 Aug; 23(3):615-32, vii-viii. PubMed ID: 17631237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and disease burden of herpes zoster in the population aged ≥50 years in China: Data from an integrated health care network.
    Sun X; Wei Z; Lin H; Jit M; Li Z; Fu C
    J Infect; 2021 Feb; 82(2):253-260. PubMed ID: 33359014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
    Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
    J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herpes zoster in Germany: quantifying the burden of disease.
    Ultsch B; Siedler A; Rieck T; Reinhold T; Krause G; Wichmann O
    BMC Infect Dis; 2011 Jun; 11():173. PubMed ID: 21679419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of herpes zoster (shingles) and postherpetic neuralgia.
    Johnson RW; Whitton TL
    Expert Opin Pharmacother; 2004 Mar; 5(3):551-9. PubMed ID: 15013924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.